Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
Abstract For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complica...
Saved in:
Main Authors: | Scott W. Canna (Author), Grant S. Schulert (Author), Adriana de Jesus (Author), Alex Pickering (Author), Hermine Brunner (Author), Massimo Gadina (Author), Stewart Levine (Author), Raphaela Goldbach-Mansky (Author), Jonathan Boutelle (Author), Rashmi Sinha (Author), Fabrizio DeBenedetti (Author), Alexei Grom (Author), on behalf of the NextGen 2019 Participants (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022
by: Rashmi Sinha, et al.
Published: (2024) -
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study
by: Fabrizio de Benedetti, et al.
Published: (2024) -
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
by: Grant Schulert, et al.
Published: (2024) -
The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
by: Scott W. Canna, et al.
Published: (2024) -
The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis
by: Najla Aljaberi, et al.
Published: (2020)